Stifel lifts Danaher price target to $260, citing strong growth outlook
Stifel raised its price target on Danaher Corp. to $260, up from $220, and kept a Buy rating. The firm said the target implies roughly an 11% premium to the current share price of $233.86 and reflects expectations of more than 5% organic growth, driven by Cytiva. Danaher reported third‑quarter 2026 adjusted earnings of $2.11 per share on revenue of $6.6 billion, with 8.5% revenue growth and a 29.0% adjusted operating profit margin.
Why it matters
Stifel’s higher target suggests the analyst expects the stock to appreciate, which could influence investor sentiment and trading activity. The firm’s view also highlights confidence in Danaher’s growth prospects despite respiratory‑segment concerns.
Key facts
- 1Stifel set a new price target of $260, up from $220. investing.com
- 2The $260 target implies about an 11% premium to the market price of $233.86. investing.com
- 3Stifel expects Danaher to achieve more than 5% organic growth, above management’s 4‑5% guidance. investing.com
- 4Danaher reported adjusted earnings of $2.11 per share for Q3 2026. investing.com
- 5Quarterly revenue was $6.6 billion. investing.com
- 6Revenue grew 8.5% year over year. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.